Antishudder Performance of Low-Molecular-Weight Alkenylsuccinimides

Low Molecular Weight Heparin Overdose: A 10 Year Case Series

  Background: Low molecular weight heparin (LMWH) is used for the treatment and prevention of coagulative disorders. Few patients receiving therapeutic doses of LMWH develop major hemorrhage. Currently there are few reports in the literature on acute overdose on adults.  In this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. Method...

Low molecular weight heparin.

Low Molecular Weight Micelles

I.F. Uchegbu et al. (eds.), Fundamentals of Pharmaceutical Nanoscience, DOI 10.1007/978-1-4614-9164-4_2, © Springer Science+Business Media New York 2013 Abstract Low molecular weight amphiphile micelles are formed from the selfassembly of comparatively hydrophilic amphiphiles (molecular weight <1,500 Da). These structures may be spherical or present as nanofi bres in the case of peptide amphiph...

Multicomponent low molecular weight gelators.

Low molecular weight gelators (LMWG) self-assemble in solution into one-dimensional objects such as fibres or tapes. The entanglement of these fibres or tapes results in the formation of a network and a gel. In general, LMWG are investigated as single component systems. However, there are significant potential opportunities from mixed LMWG systems, which are rarely investigated. Here, we discus...

Perioperative Low - Molecular - Weight Heparin

In previous randomised clinical trials of thromboprophylaxis after total hip replacement, low-molecular-weight heparin has been given for an arbitrary 7 to 14 days. The risk factors are mainly perioperative and it is possible that a shorter course may be adequate. We assessed the safety and effectiveness of a three-day course. We assessed 156 primary THR patients after randomisation to either a...